|
19 Mar 2022 $0.395 https://seekingalpha.com/article/4429440-immutep-relatively-unknown-pure-play-on-lag3-surrounded-by-major-pharma https://www.businesswire.com/news/home/20220304005561/en/ https://news.bms.com/news/corporate-financial/2022/U.S.-Food-and-Drug-Administration-Approves-First-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-rmbw-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma/default.aspx |
